Incidence of infectious complications in highly sensitized renal transplant recipients treated by rituximab: A case-controlled study

Transplantation

Volumn 90, Issue 11, 2010, Pages 1180-1184

  Scemla, Anne ^a,b   Loupy, Alexandre ^a   Candon, Sophie ^a,b   Mamzer, Marie France ^a   Martinez, Frank ^a   Zuber, Julien ^a,b   Sberro, Rebecca ^a   Legendre, Chistophe ^a,b   Thervet, Eric ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Immunization; Renal transplantation infection; Rituximab

Indexed keywords

CREATININE; RITUXIMAB;

ADULT; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; INFECTION RISK; INFECTIOUS COMPLICATION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MALE; MYCOSIS; PERITONITIS; PNEUMOCYSTOSIS; PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SENSITIZATION; SEPSIS; VIRUS INFECTION;

ADULT; ANTIBODIES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COMMUNICABLE DISEASES; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; PARIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 78650310523     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181fa941b     Document Type: Article

References (18)

1. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
2. Grim SA, Pham T, Thielke J, et al. Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. Clin Transplant 2007; 21: 628.
3. Zarkhin V, Li L, Kambham N, et al. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 2008; 8: 2607.
4. Peters HP, van de Kar NC, Wetzels JF. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: Report of four cases and review of the literature. Neth J Med 2008; 66: 408.
5. Gallon L, Chhabra D. Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient. Am J Transplant 2006; 6: 3017.
6. Tam C, Seymour JF, Brown M, et al. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies. Haematologica 2005; 90: 700.
7. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: Meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009; 68: 25.
8. Kamar N, Milioto O, Puissant-Lubrano B, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010; 10: 89.
9. Becker YT, Becker BN, Pirsch JD, et al. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4: 996.
10. Tyden G, Genberg H, Tollemar J, et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87: 1325.
11. Kee T, Lu YM, Vathsala A. Spectrum of severe infections in an Asian renal transplant population. Transplant Proc 2004; 36: 2001.
12. USRDS 2003 Annual Report. Available at: http://www.usrds.org/atlas- 2003.htm. Accessed April 6, 2010.
13. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68.
14. Kamar N,Sandres-Sauné K, RostaingL. Influence ofrituximab therapy on hepatitis C virus RNA concentration in kidney-transplant patients. Am J Transplant 2007; 7: 2440.
15. Bower M, Powles T, Williams S,et al. Brief communication: Rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 2007; 147: 836.
16. Thaunat O, Mamzer-Bruneel MF, Agbalika F, et al. Severe human her-pesvirus-8 primary infection in a renal transplant patient successfully treated with anti-CD20 monoclonal antibody. Blood 2006; 107: 3009.
17. KumarD,Gourishankar S,MuellerT,et al.Pneumocystis jiroveciipneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient. Transpl Infect Dis 2009; 11: 167.
18. De Castro N, Xu F, Porcher R, et al. Pneumocystis jirovecii pneumonia in renal transplant recipients occurring after prophylaxis discontinuation: A case control-study. Clin Microbiol Infect 2010; 16: 1375.